Glioblastomas are heterogeneous tumors displaying regions of necrosis, proliferation, angiogenesis, apoptosis and invasion. SPARC, a matricellular protein that negatively regulates angiogenesis and cell proliferation, but enhances cell death/desmosis from matrix, is upregulated in gliomas (Grades II–IV). We previously demonstrated that SPARC promotes invasion while concomitantly decreasing tumor growth, in part by decreasing proliferation of the tumor cells. In other cancer types, SPARC has been shown to influence tumor growth by altering matrix production, and by decreasing angiogenesis via interfering with the VEGF-VEGFR1 signaling pathway. We therefore examined whether the SPARC-induced decrease in glioma tumor growth was also, in part, due to alterations in matrix and/or decreased vascularity, and assessed SPARC-VEGF interactions. The data demonstrate that SPARC upregulates glioma matrix, collagen I is a constituent of the matrix and SPARC promotes collagen fibrillogenesis. Furthermore, SPARC suppressed glioma vascularity, and this was accompanied by decreased VEGF expression and secretion, which was, in part, due to reduced VEGF165 transcript abundance. These data indicate that SPARC modulates glioma growth by altering the tumor microenvironment and by suppressing tumor vascularity through suppression of VEGF expression and secretion. These experiments implicate a novel mechanism, whereby SPARC regulates VEGF function by limiting the available growth factor. Because SPARC is considered to be a therapeutic target for gliomas, a further understanding of its complex signaling mechanisms is important, as targeting SPARC to decrease invasion could undesirably lead to the growth of more vascular and proliferative tumors.

Key words: SPARC; matrix; collagen I; vascularity; VEGF(R1/2); gliomas

Glioblastomas are the most malignant grade of glioma. Treatment of these tumors is difficult, because of their high degree of heterogeneity. Heterogeneity is present at the cellular level, where different clonal populations may have arisen over time, and this makes it difficult to design a single treatment that will attack all tumor cells. Heterogeneity also occurs at the phenotypic level, where, simultaneously, different regions within the tumor may be undergoing different biological processes such as necrosis, tumor cell migration, proliferation, angiogenesis and apoptosis and invasion into the adjacent brain.

Present-day capabilities of interrogating the genetic and protein profiles of tumors and identifying entire altered signaling pathways make it possible to better design therapeutic approaches to target key proteins or their downstream effectors. Such studies indicate that the cancer profile is closely related to the embryonic profile, suggesting that many of the cancer-related genes are developmental genes that have been inappropriately re-expressed. For gliomas, one such protein is secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40.

SPARC is a secreted glycoprotein belonging to the matricellular family of proteins that mediate cell-matrix interactions that affect diverse biological functions including proliferation, survival, adhesion and migration. They are expressed during embryonic development, and in adult tissues their expression is limited to tissues undergoing repair or remodeling due to wound healing or natural processes. In the developing brain, SPARC is expressed in angiogenic microvasculature, and in the adult brain it is expressed in the locus coeruleus, ganglion cells, and astrocytes of the adult retina, but not in cells of the cerebral cortex.

We have previously confirmed that SPARC protein is undetectable in normal adult cerebral cortex; however, it was found to be highly expressed in gliomas of all grades, in both the tumor cells and angiogenic endothelial cells, and it was upregulated in angiogenic endothelial cells and reactive astrocytes in the tumor-adjacent brain tissue. We and others have demonstrated that SPARC promotes invasion in vivo and in vitro. We demonstrated that SPARC-induced tumor invasion was associated with decreased tumor cell proliferation and overall tumor volume, suggesting that the ability of SPARC to negatively impact cell growth may be by promoting a migratory versus a proliferative phenotype in gliomas.

The negative effects of SPARC on tumor growth that result from its inhibition of tumor cell proliferation are likely complemented by the ability of SPARC to negatively affect endothelial cell proliferation. This modulation may be accomplished in part by inhibiting growth factor signaling pathways, including those regulated by VEGF, which is a major contributor to glioma angiogenesis. SPARC has been shown to negatively regulate endothelial cell proliferation by attenuating VEGF-VEGFR1 signaling by binding to VEGF and inhibiting the growth factor binding to its receptor. Recent data, however, indicate that VEGF-VEGFR signaling is not restricted to endothelial cells, as the receptors for VEGF have been identified on tumor cells, including human glioma tissues, primary glioma cells, and established cell lines. This suggests that SPARC could negatively impact not only glioma angiogenesis but also glioma cell proliferation and overall tumor growth through inhibition of the VEGF-VEGFR signaling pathway.

SPARC also affects matrix composition. Depending on the matrix concentration and regional expression within a tumor, the matrix may affect cytokine regulation of endothelial cell proliferation. For example, SPARC promotes the synthesis and secretion of several collagens including collagen I. When GBM spheroids...
were grown in collagen matrices, increasing collagen I concentration correlated with decreased spheroid growth in vitro. In vivo, collagen I decreased glioma tumor growth in a flank model. In relevance to this study, Chlenski et al. found that SPARC impaired tumor growth of human embryonic kidney 293 xenograft tumors, and this was accompanied by inhibited angiogenesis and increased collagen I.

These studies suggest that the multiple effects of SPARC on endothelial and tumor cell growth and changes to the tumor microenvironment likely combine to thwart angiogenesis and tumor growth. Therefore, we hypothesized that the previously reported suppressed tumor growth in the SPARC-transfected glial tumors, which was accompanied by decreased tumor proliferation, might be accompanied by increased matrix production and inhibition of tumor vascularity. Furthermore, we hypothesized that SPARC inhibition of the VEGF-VEGFR signaling in endothelial and/or glioma cells would be involved. To test this hypothesis, control- and SPARC-transfected glioma cells were assessed in vivo and in vitro for SPARC-induced changes in matrix production, vascularity, VEGF-VEGFR expression and SPARC-VEGF interaction.

Material and methods

Cell culture and reagents

Standard tissue culture reagents were purchased from Gibco-BRL (Gaithersburg, MD). Fetal bovine serum (FBS), Superscript First-Strand Synthesis System, Platinum Taq DNA Polymerase, SeeBlue Plus 2 and MagicMark XP Western Standards were obtained from Invitrogen (Carlsbad, CA). Noble agar was purchased from Difco Laboratories (Livonia, MI). The BCA protein assay kit was purchased from Pierce Chemical (Rockford, IL). Anti-SPARC (Haematologic Technologies, Essex Junction, VT, #AO05031), anti-human procollagen I (Chemicon, Millipore, Bedford, MA, #MAB1912), anti-factor VIII (Dako, Carpinteria, CA, #A0082), anti-VEGF (Santa Cruz, Santa Cruz, CA, #SC-7269), anti-VEGF (clone 1D7, a kind gift from Dr. Rolf Breken), VEGFR1/Flt-1 (Santa Cruz, CA, #SC-316), VEGFR2/FLK-1 (Santa Cruz, CA, #SC-6251), VEGFR2/FLK-1 (LabVision/Neomarkers, Fremont, CA, #RB-9239) and anti-actin (Santa Cruz, CA, #SC-1616) were obtained as indicated. ECL kits were purchased from Amersham Biosciences (Piscataway, NJ). Immobilon-P membranes were purchased from Millipore (Bedford, MA) and blotting grade blocker non-fat dry milk was from Bio-Rad Laboratories (Hercules, CA). RNeasy Lipid Tissue mini kit was purchased from Qiagen (Valencia, CA) and protein G-agarose was from Roche Diagnostics (Indianapolis, IN).

Control and SPARC-transfected U87MG cells

Derivation of the U87MG-derived parental control clone P [U87T2], the P-derived SPARC-transfected clones (S1 [C2A4] and S2 [A2b2]) and P-derived vector controls (VC1 and VC2) is as previously reported. The SPARC- and vector-transfected clones were maintained in 400 µg/ml neomycin (G418) and 1 µg/ml puromycin, whereas the parental control clone was maintained only in G418.

Rat brain xenograft implantation and tissue processing

Vector control- and SPARC-transfected cells (5 x 106) were implanted using IACUC-approved protocols as previously reported. Rats were sacrificed 7 days later. The brains were anesthetized, and death followed via cardiac puncture (i.e., perfusion with 250–400 ml of sterile 0.9% saline solution and fixation with 250–400 ml of 10% formalin). The brains were removed and stored in 10% formalin for at least 24 hr. Formalin-fixed rat brains were placed in a 200–400 g coronal rat brain matrix (Activational Systems, Warren, MI) and sliced into 2-mm blocks. These blocks were then routinely processed, paraffin-embedded and serially sectioned at 5 µm. n = 3–6 rats/cdene.

Diastase digestion and periodic acid Schiff reaction

Periodic acid Schiff (PAS) staining was performed as published with minor modifications. The 5-µm sections were dried in a 60°C oven for 1 hr and routinely deparaffinized to water. Untreated sections (water) and paired sections in diastase solution (0.1 g/100 ml water) were incubated for 1 hr at 37°C. Sections were washed in running water for 5 min and placed in 0.5% periodic acid solution. Sections were then rinsed in four changes of distilled water, incubated in Schiff’s reagent for 15 min and washed well in water for 10 min. Sections were then stained in Biocare hematoxylin for 15 s, washed in water, placed in ammonia water to blue, washed, dehydrated through 95% (2 times) and 100% ethanol (2 times), cleared in xylene (2 times) and mounted. Liver sections (± diastase) were used as controls.

Picrosirius red staining

Staining was performed as published with minor modifications. Sections were deparaffinized and hydrated to water and exposed to 0.1% picrosirius red for 1 hr at room temperature, and washed in 1% acidified water twice for 15 min each. Sections were washed, dehydrated in alcohols, cleared in xylene and mounted. Sections are examined with polarized light microscopy. Thicker and more closely packed fibrils are orange to red, whereas thinner fibrils are yellow to green.

Immunohistochemistry

Immunohistochemistry was performed using the Biocare Medical Nemesis 7200 (Concord, CA) stainer and reagents for anti-SPARC antibody (1:13,333 dilution in 0.25% BSA in PBS), and anti-procollagen I antibody (1:250 dilution), anti-factor VIII (1:1,200), anti-VEGF antibody (#SC-7269, 1:250) or anti-VEGFR2 antibody (1:3,000) were all diluted in DaVinci antibody diluent. The 5-µm sections were dried in a 60°C oven for 1 hr and routinely deparaffinized to water. SPARC and VEGFR2 were detected after heat-induced antigen retrieval using citrate buffer (pH 6.0) as previously described. VEGF, factor VIII and procollagen I were detected after treatment with 0.4% pepsin in 0.01 N HCl at 37°C for 50, 90 or 45 min, respectively. Control sections were processed omitting the primary antibody and substituting with the appropriate immunoglobulin isotype.

Endothelial cell counts

For each tumor, sections were scanned at 10× magnification to identify hotspots or areas of densest factor VIII staining. Then 2–6 fields/section (depending on tumor area) were captured at 40× magnification. To count factor VIII-positive cells, images at 40× magnification were printed as 8.5 by 11” photographs. Any single cell that stained positively for factor VIII in a field was counted in each case. A visible lumen was not required. All images were counted by 3 investigators, and the values were averaged. For each cell line, 3–6 tumors were assessed and averaged. The results are presented as the average number of factor VIII-positive endothelial cells/40× magnification/clone ± the SD.

Media and lyse preparation

For monolayer culture, equal numbers of cells were plated for 72 hr before media and lysates were collected. For spheroid culture, cells (4 x 106) were seeded on agar-coated T75 flasks for 72 hr as previously reported. Conditioned media were collected in serum-free conditions with constant medium volumes, and protein lysates were extracted with a single-detergent lysis buffer as previously reported. The protein concentration was determined using the BCA protein assay. Media and lysates were used for the coimmunoprecipitation and Western blot analyses.

Coimmunoprecipitation of VEGF and SPARC

One milliliter of lysate containing 200–500 µg of total protein was precleared overnight with 25 µl of protein G-agarose beads. Either 2.7 µg of VEGF antibody (#PC315), 5.0 µg VEGF antibody...
(clone 12D732) or 1 μg of mouse monoclonal SPARC antibody (#AON5031) was added to the precleared lysates, and the samples were then incubated at 4°C with mixing for 1 hr. Protein G-agarose beads (25 μl) were added and the samples were incubated with mixing overnight at 4°C. The next day, the beads were microcentrifuged for 20 s at 12,000g, and washed with 1 ml of 1× lysis buffer for 20 min at 4°C with mixing. This was repeated for a total of 3 washes. After removing the final wash, 30 μl of 2× SDS gel loading buffer was added, and the proteins were denatured by heating to 100°C for 3 min. The protein G-agarose was removed by centrifugation for 20 s at 12,000g at room temperature, and the supernatants were transferred to fresh tubes. Immunoprecipitated proteins were subjected to 13.5% SDS-polyacrylamide gel electrophoresis and processed as described under Western blot analysis.

**Immunoprecipitation of VEGFR2**

Spheroid lysates (1 ml of 300 μg/ml) were precleared as described previously and then incubated with either 5 μg of anti-Flt-1 (#SC316) or anti-Flk-1 (SC6251) antibodies for 1 hr. Protein-G agarose beads (25 μl) were then added to each tube and incubated and washed as described earlier. SDS gel loading buffer (35 μl) was added and the samples were boiled for 3 min at 100°C and centrifuged to remove beads. Samples were electrophoresed through 7.5% SDS-polyacrylamide gels, transferred, and subjected to Western blot analysis as follows.

**Western blot analysis**

For total proteins, media (21 μl) and lysates (18 μg) were subjected to 13.5% SDS-polyacrylamide gel electrophoresis. For all Western blots, the molecular weight standard, a mixture of 10 μl MagicMark XP Western Standard and 5 μl SeeBlue Plus 2 pre-stain standard was run on each gel. Resolved proteins were transferred to an Immobilon P membrane in a Tris-glycine transfer buffer (48 mM Tris, 39 mM glycine, 20% v/v methanol; pH 9.2).

Membranes for total and immunoprecipitated proteins were dried at room temperature, re-wet in methanol, rinsed in Tris-buffered saline (TBS; pH 7.5) and then blocked for 1 hr at room temperature in 5% blotting grade non-fat dry milk blocker in TBS. The membranes were incubated with anti-SPARC (1:8,000; #AON5031), anti-VEGF (1:500; #SC-7269), anti-VEGFR1 (1:100; #SC316) or anti-VEGFR2 (1:200, SC-6251; or 1:500, RB-9239) antibodies in 2.5% blocker in TBS for 1 hr at room temperature. The membranes were then washed twice in TBST (TBS plus 0.1% Tween-20) and twice in 2.5% blocker in TBS. Membranes were incubated with appropriate secondary HRP-linked antibodies (in 2.5% blocker in TBS) for 30 min at room temperature, and then washed 4 times in TBST. SPARC and VEGF proteins were detected using the ECL kit, following the manufacturer’s instructions. For loading control, the dried membranes were reprobed for actin (1:500 dilution).

**VEGF and VEGFR RT-PCR**

Total RNA was extracted from cell lines and human tissues (collected under an approved IRB protocol) using the RNaseasy Lipid Tissue mini kit, according to the manufacturer’s protocol and as previously reported.33 cDNA synthesis was performed using Superscript First-Strand Synthesis System with oligo(dt) at 42°C for 50 min. PCR was performed with Platinum Taq DNA Polymerase and gene-specific primers (Table I) for VEGF,34 VEGF165,35 VEGFR136 and VEGFR236 using an Eppendorf Master cycler 9600. For VEGF reactions, GAPDH primers33 were coamplified as a control for cDNA integrity. An initial denaturation at 94°C for 1 min was followed by 27 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 1 min, extension at 72°C for 2 min and a single cycle for final extension for 10 min at 72°C. For VEGF165 primers, 94°C for 30 sec was followed by 63°C for 45 sec, 72°C for 1 min for 30 cycles and 72°C for 10 min. For VEGFR1 and VEGFR2 reactions, GAPDH was coamplified with VEGFR1 but amplified separately for VEGFR2 because the product sizes were similar. The initial 94°C for 10 min was followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 63°C for 45 sec, extension at 72°C for 1 min and a single cycle for final extension for 10 min at 72°C. A negative control included RT-PCR without cDNA synthesis to ensure that no amplification was derived from contaminating DNA. The RT-PCR products were visualized on 1.5% agarose gel with ethidium bromide staining.

**qRT-PCR**

Quantitative RT-PCR for VEGF165 was performed as previously reported.33 A primer optimization step was tested for each set of primers to determine the optimal primer concentrations. Primers, 10 μl of 2× SYBR Green Master Mix (Invitrogen, Carlsbad, CA) and 8 μl of a 1:30 dilution of the same cDNA used for the RT-PCR analyses were resuspended in a total volume of 20 μl of PCR amplification solution, VEGF165 primers (Table I) were used to amplify 110 bp and VEGF 60 bp fragments. The sense primers are in exon 4 and the antisense primers cover the junction between exons 5 and 6.38 S12 was amplified as a control. Reactions were run on an ABI Prism 7000 Sequence Detection System (Applied Biosciences, Foster City, CA). The cycling conditions composed of 4-min polymerase activation at 95°C and 40 cycles, 90°C for 30 sec, 60°C for 30 sec and 72°C for 1 min. Cycle threshold (Ct) values were obtained from the ABI 7000 software. S12 levels were also determined in the same run for each RNA sample

| TABLE I – RT-PCR PRIMERS |
|---------------------------|
| Primer sequence | Ref |
| RT-PCR |
| VEGF | Sense | 5’-TCG GGC CTC CGA AAC CAT GA-3’ | 34 |
| VEGF165 | Sense | 5’-CCT GGT GAG AGA TCT GGT TC-3’ | 35 |
| VEGFR1 | Sense | 5’-GAG ATG AGC TTC CTA CAG CAC-3’ | 36 |
| VEGFR2 | Sense | 5’-CTC GAA TTC AGA TCT TTC ATA GTG ATG GGC TC-3’ | 36 |
| qRT-PCR |
| S12 | Sense | 5’-TGC TGG AGG TGT AAT GGA G-3’ | 37 |
| VEGF165 110 bp | Sense | 5’-ATG CGG ATC AAA CCT CAAC AA-3’ | 38 |
| VEGF165 60 bp | Antisense | 5’-TTC CTA CAG CAC AAC AAA TG-3’ | 38 |
as controls. Fold change of relative mRNA expression was determined using the 2-ΔΔCT method as previously reported.39 qRT-PCR reaction products were run on an agarose gel to confirm the product size and specificity (data not shown).

**Results**

**SPARC increases collagen I production and fibrillogenesis**

SPARC not only increases the synthesis of collagen I,24 but also regulates the processing of procollagen I and collagen in dermal fibroblasts.40 Therefore, to assess changes in matrix production, processing and fibrillogenesis because of SPARC expression, control- (−SPARC) and SPARC (+SPARC)-expressing U87 glioma cells (Fig. 1a) were implanted into nude rat brains, and Day 7 control and SPARC-expressing tumors were obtained (Fig. 1b). Tumor sections were subjected to 3 different assays known to detect collagen, including the periodic acid Schiff reaction (PAS) with or without diastase treatment, procollagen I immunohistochemistry and picrosirius red staining with polarized light microscopy (Fig. 1b).

PAS stains glycogen and matrix proteins, including collagen, magenta. Diastase treatment removes any glycogen, and therefore comparisons between the staining intensity with or without diastase treatment can be used to characterize tissue constituents. Using this method, we observed no changes in intensity of the PAS staining, comparing sections with versus without diastase treatment in either the control tumors or the SPARC-expressing tumors. In contrast, a clear difference was observed for the control liver tissues. These data indicate that glycogen is not a major constituent of the tumors and that the magenta staining is due to matrix proteins. The stronger intensity of PAS staining in the SPARC-expressing tumors compared to the control tumors indicates that the SPARC-expressing tumors have more matrix (Fig. 1b).

To determine whether the matrix detected by PAS staining included collagen, tumor sections were subjected to immunohistochemical analysis using an antibody that detects only human procollagen I. Both the control and the SPARC-expressing tumors expressed procollagen I. However, the SPARC-expressing tumors were more intensely stained, suggesting greater levels of procollagen I synthesis (Fig. 1b). This was supported by the more intense staining of the SPARC-expressing tumors with picrosirius red, a compound that stains collagen bright pink (data not shown).

Picrosirius red staining is also used to detect immature and mature collagen fibrils under polarized light. When examined under polarized light, only the SPARC-expressing tumors had immature and mature collagen fibers (Fig. 1b), suggesting that SPARC expression enhanced collagen I processing and fibrillogenesis.

**SPARC decreases vascularity**

Because matrix impacts vascularity,23 and SPARC-expressing tumors had more matrix, we evaluated the effects of SPARC expression on vascularity. Serial sections were stained with factor VIII (Fig. 2a), and the average number of factor VIII-positive endothelial cells/field was measured for each clone and plotted (Fig. 2b). The SPARC-expressing tumors had significantly less vascularity than the control tumors (*p ≤ 0.0001).
In our study, we made the following observations. In vivo, using xenograft implantation of U87MG control- and SPARC-transfected clones, we found that increased SPARC expression correlated with increased matrix production, procollagen I expression and secretion in vitro using spheroid culture.

VEGF expression and secretion was observed in the control cells and VEGF189. However, increased SPARC expression correlated with a decrease in VEGF expression and secretion, thereby attenuating the VEGF-VEGFR1/2 signaling mechanisms.

**Discussion**

The lack of coimmunoprecipitation with VEGF indicates that the decrease in vascularity induced by SPARC is not because of the inhibition of VEGF-VEGFR1 paracrine signaling in endothelial cells. Furthermore, the lack of coimmunoprecipitation with VEGF and the lack of VEGFR1 on the glioma cells indicate that the decrease in vascularity induced by SPARC is also not because of the inhibition of VEGF-VEGFR1 autocrine signaling in glioma cells.

The U87 cell lines express VEGFR2

In a proposed mechanism involving SPARC-integrin interaction, SPARC upregulates VEGF expression and autocrine stimulation of prostate cancer cell growth via VEGF-VEGFR2 signaling. Such a mechanism could lead to a large increase in VEGF expression that could also effect overall vascularity by disrupting vessel integrity. Therefore, we examined our cells for VEGFR2 expression. RT-PCR analysis demonstrated the presence of VEGFR2 transcripts in the U87-derived cell lines (Fig. 3c). This was confirmed by Western blot analysis (Fig. 3d) and immunoprecipitation (Fig. 3e). Finally, immunohistochemistry (Fig. 3f) demonstrated that VEGFR2 expression was observed in tumor cells in vivo.

**SPARC does not mediate paracrine VEGF-VEGFR2 signaling by increased secretion of VEGF**

Because the cell lines expressed VEGFR2, and SPARC has been implicated in upregulating VEGF expression, we determined whether increased SPARC expression correlated with increased VEGF expression. Low endogenous SPARC expression was confirmed in the tumor cells of control tumors, and increased expression of SPARC was observed in the SPARC-transfected tumor cells (Fig. 1b). Conversely, high levels of VEGF were observed in the controls and much lower levels were observed in the SPARC-transfected tumors (Fig. 4a). The data suggest that SPARC decreases tumor growth by suppressing VEGF expression and secretion, thereby attenuating the VEGF-VEGFR1/2 signaling mechanisms.

**Enhanced SPARC expression correlates with decreased VEGF expression and secretion in vitro**

To determine whether the decrease in VEGF observed in vivo was due to direct SPARC expression and not an environmental influence, the cells were assessed in vitro using spheroid culture. VEGF expression and secretion was observed in the control cells (P, VC1, VC2); however, less protein was observed in the lysates (L-VEGF) of SPARC-transfected cells and none was secreted (M-VEGF) in the SPARC-transfected cells (Fig. 4b). Two VEGF isoforms were expressed in the control cells, and in comparison with the positive control (VEGF165), are presumed to be VEGF165 and VEGF189.

**SPARC expression correlates with a decrease in VEGF165 transcript**

RT-PCR was performed to determine whether the decrease in VEGF protein correlated with the decreased transcript. All 4 major isoforms (206, 189, 165 and 121) were detected in the control and SPARC-transfected cells (Fig. 4c). However, increased SPARC expression correlated with a specific reduction in the VEGF165 transcript, which was confirmed using real-time RT-PCR and 2 sets of VEGF165-specific primers (Fig. 4d).

**Discussion**

In our study, we made the following observations. In vivo, using xenograft implantation of U87MG control- and SPARC-transfected clones, we found that increased SPARC expression correlated with increased matrix production, procollagen I expression...
and collagen I fibrillogenesis. Increased matrix was associated with decreased microvascularity, which corresponded to decreased VEGF expression.

In vitro, we found that SPARC reduced VEGF expression and secretion, and that this was, in part, accomplished by reduced VEGF165 transcript abundance.

We have previously demonstrated that enhanced SPARC expression increases glioma invasion and concomitantly decreases glioma growth and tumor volume. The decrease in growth was, in part, due to a decrease in tumor cell proliferation. However, as SPARC is a negative regulator of angiogenesis, we proposed that SPARC could affect overall glioma growth by affecting vascularity. As SPARC also affects matrix synthesis, and matrix can have a profound effect on vascularity, we determined the effects of SPARC on glioma matrix production.

We found that the number of factor VIII-positive endothelial cells was significantly lower in the SPARC-expressing tumors indicating that SPARC reduced tumor vascularity. In addition, the SPARC-expressing tumors were found to produce more matrix as assessed by PAS staining. This increase was, in part, due to an increase in procollagen I synthesis as determined by immunohistochemistry, and increased collagen I deposition and fibrillogenesis as determined by polarized light microscopy of picrosirius red-stained sections.

Our results agree with those from the Cohn Laboratory. Their data indicated that SPARC enhanced matrix production and decreased angiogenesis of human embryonic kidney 293 cells implanted into the flanks of athymic nude mice. However, our results do differ with respect to the source of collagen I, which was shown to be from host stromal cells in their model and from tumor cells in our model. Since U87 cells are known to express collagen I and as we used an antibody that detects only human procollagen I, we conclude that the source of collagen I in our

**Figure 3** – Assessment of SPARC, VEGF and VEGFR expression. (a and b) Conditioned media (CM) from control (VC2) and SPARC-transfected (S2) spheroids were subjected to immunoprecipitation (IP) with antibody to (Ab) to either VEGF or SPARC, followed by Western immunoblotting (IB) with anti-VEGF antibody (a) or anti-SPARC antibody (b). (Panel a) Lane 1: VEGF antibody alone (control), Lane 2: anti-VEGF IP of VEGF protein (control), Lane 3: IP of VC2-CM minus primary Ab (control), Lane 4: anti-SPARC IP of VC2-CM, Lane 5: anti-VEGF IP of VC2-CM, Lane 6: anti-SPARC IP of S2-CM, Lane 7: anti-VEGF IP of S2-CM, Lane 8: empty lane, Lane 9: VEGF protein (for size standard) and Lane 10: molecular weight standard. Arrow: VEGF antibody immunoprecipitated VEGF only from control VC2-CM. (Panel b) Lane 11: SPARC antibody alone (control), Lane 12: empty lane, Lane 13: IP of VC2-CM minus primary Ab (control), Lane 14: Anti-SPARC IP of VC2-CM, Lane 15: Anti-VEGF IP of VC2-CM, Lane 16: Anti-SPARC IP of S2-CM, Lane 17: anti-VEGF IP of S2-CM, Lane 18: empty lane, Lane 19: SPARC protein (for size standard) and Lane 20: molecular weight standard. Arrow: SPARC antibody immunoprecipitated SPARC only from control VC2- and S2-CM. Bands at 55 and 23 KDa are IgG heavy and light chains. Note that no coimmunoprecipitation was observed using either antibody, even when blots were overexposed as illustrated. (c) RT-PCR analysis of VEGFR1 (Flt-1) and VEGFR2 (Flk-1). (Top gel) Lane 1: molecular weight standard, Lane 2: control parental U87 cells, Lane 3: vector control VC1, Lane 4: vector control VC2, Lane 5: SPARC-transfected clone S1, Lane 6: SPARC-transfected clone S2, Lane 7: normal brain N141, Lane 8: astrocytoma A203, Lane 9: anaplastic astrocytoma AA152, Lane 10: GBM373, Lane 11: –RT-control, Lane 12: H2O Control reaction without cDNA. (Middle gel) GAPDH control coamplification of GAPDH in the same samples used with VEGFR1 primers to confirm integrity of cDNA. Note the lack of VEGFR1 in U87-transfected cells. (Bottom gel) VEGFR2 RT-PCR analysis of the same samples as the top gel. (d) Western blot analysis of VEGFR2. Lane 1: SPARC-transfected clone S2, Lane 2: vector-transfected control VC2, Lane 3: parental U87, Lane 4: THP-1-positive VEGFR2 control and Lane 5: molecular weight standard. The VEGFR2 blot was stripped and reprobed for actin as control for loading. (e) Immunoprecipitation (IP) of VEGFR2 for the same samples in panel b, followed by Western blotting (IB) for VEGFR2. VEGFR2 is present in U87 parental and transfected cells. (f) VEGFR2 immunohistochemistry in normal rat brain, controls (P, VC2) and SPARC-transfected S2 tumor. Magnifications as indicated. VEGFR2 transcript and protein are present in the U87 control and SPARC-transfectants.
Tumor model was from the human tumor cells. Differences may be due to tumor type or microenvironmental influences as we used orthotopic implantation versus flank implantation.

Collagen I has been associated with decreased T98G glioma growth and invasion in vivo. However, those in vivo studies were subcutaneous flank implantations and the microenvironment is vastly different from the brain, which could account for a lack of invasion. Interestingly, it has been shown that collagen concentration and regional expression in the tumor are important in its function. Using GBM spheroids, high collagen concentration correlated with decreased growth in the spheroid core and increased migration of tumor cells at the periphery. These observations correlate well with our model, in which enhanced SPARC expression decreases overall tumor growth and increases invasion.

SPARC has been implicated in 2 mechanisms of VEGF-VEGFR signaling, which can affect both autocrine and paracrine signaling. In 1 mechanism, SPARC binds directly to VEGF, which inhibits VEGF binding to VEGFR1, a receptor present on endothelial and some tumor cells. In characterizing our tumor model, we found that the U87-derived glioma cells expressed and secreted VEGF. However, these cells do not express VEGFR1, an observation in agreement with another report. This lack of receptor expression, therefore, precludes a VEGF-VEGFR1 mechanism that would be disrupted by SPARC in the tumor cells. Exploring the possibility that SPARC binding to VEGF could decrease vascularity by attenuating VEGF-VEGFR1 signaling in endothelial cells, we investigated whether SPARC and VEGF coimmunoprecipitated. We saw no interaction between the proteins, eliminating this mechanism as well. The lack of coimmunoprecipitation is not surprising in light of the inverse correlation of SPARC and VEGF expression, as discussed later.

In the second proposed mechanism, SPARC expression in prostate tumor cells induces an increase in VEGF expression, which upregulates VEGF binding to VEGFR2 present on the tumor cells, thereby promoting tumor growth. However, the authors found the opposite results using M21 melanoma cells and suggested that these differences are because of the cell type-specific differences. In this study, the U87-derived cells demonstrated the presence of VEGFR2, a result that contrasts another report, perhaps because of the differences in the efficacy of the primers used. Therefore, we further validated our RT-PCR observations using Western blot, immunoprecipitation and immunohistochemical analyses. The presence of VEGFR2 and the secretion of VEGF by the control tumors may indeed contribute to their growth. However, the effect of SPARC on these cells was to decrease VEGF expression, an observation that agrees with that reported for the melanoma cells. Therefore, we conclude that in gliomas, SPARC decreases VEGF secretion and thereby attenuates the VEGFR-VEGFR2 signaling in the U87 glioma cells, which corresponds with the decreased growth previously observed.

We investigated the mechanism whereby SPARC decreases VEGF expression, and found that SPARC suppresses VEGF165 at the transcript level and VEGF protein expression and secretion. The exact mechanisms involved are not known, but SPARC is known to alter the expression of other genes. In addition, several

**Figure 4** - Immunohistochemical, Western blot and RT-PCR analysis of VEGF protein and transcripts in control- (-SPARC) and SPARC- (+SPARC) transfected clones. (a) Representative tumor sections immunohistochemically stained for VEGF expression. Note the decreased VEGF expression in the SPARC-expressing tumors. (b) Control and SPARC-expressing spheroids were assessed for VEGF and SPARC expression and secretion by Western blot analysis. Actin detection was used as a loading control. Note that increased SPARC expression correlated with decreased VEGF expression and secretion. (c) RT-PCR was performed to detect all 4 major VEGF isoforms as indicated. (b and c) * indicates that the signal is on the same gel but moved closer. (d) Real-time RT-PCR analysis of the VEGF165 isoform. Note that enhanced SPARC expression is associated with decreased VEGF165 transcript abundance. P-parental clonal U87MG-derived cell line, VC1- and VC1-vector control cell lines, S1- and S2- SPARC-transfected cell lines.
reports show an inverse relationship between SPARC and VEGF expression; the more SPARC, the less VEGF, as well as the more VEGF, the less SPARC. Indeed, a study examining progression of serially passaged primary human glioma cells demonstrated that early passage tumors formation was accompanied by invasion, SPARC expression and no VEGF expression. In contrast, later passage tumors were not invasive, did not express SPARC, but had high levels of VEGF expression.

In summary, these data demonstrate that SPARC upregulates glioma ECM, collagen I is a constituent of this matrix and SPARC facilitates collagen fibrillogenesis. This increase in collagen I correlates with the suppressed tumor growth and increased invasion previously reported. In addition, SPARC suppression of glioma vascularization is accompanied by decreased VEGF expression and secretion. These data suggest another mechanism of action, whereby SPARC regulates VEGF expression rather than its function. A further understanding of the mechanisms involved is important for utilizing these proteins as therapeutic targets, as inhibiting SPARC alone could undesirably lead to more angiogenic and proliferative tumors and, conversely, targeting VEGF alone might facilitate more invasive tumors.

Acknowledgements

We thank Dr. Stacey Thomas for critical review of the manuscript, Mr. Enoch Carlton for tissue sectioning, Dr. Rolf Brekken for the VEGF clone 12D7 antibody and Drs. Clifford Les and Gary Gibson for their instruction and the use of their equipment to capture the polarized images. This research was supported by the NIH/NCI grants to S.A.R. and C.B.

References

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
2. Maher EA, Funari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, Radvanyi L. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311–33.
3. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jeness WJ, Freudentberg J, Chen X, Haigis K, Jegga AG, Kong S, Sakhthivel B, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse tumor colon models and human colon cancer. Genome Biol 2007;8:R131.
4. Bogstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002;14:686–16.
5. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2000;19:816–27.
6. Lane TF, Iruela-Arripe ML, Johnson RS, Sage EH. SPARC is a source of copolymerizing peptides that stimulate angiogenesis. J Cell Biol 1994;125:929–43.
7. Bergson C, Zhao H, Sajioh K, Duman RS, Neter EJ. Ezrin and osteonectin, two proteins associated with cell shape and growth, are enriched in the locus coeruleus. Mol Cell Neurosci 1993;4:64–73.
8. Yan Q, Sage EH, Hendrickson AE. SPARC is expressed by ganglion cells and astrocytes in bovine retina. J Histochem Cytochem 1998;46:3–10.
9. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994;8:163–73.
10. Rempel SA, Golembieski WA, Ge S, Lemeke N, Elisievich K, Mikkelson T, Gutierrez JA, SPARC: A signal of astrocytic neoplasm transformation and reactive response in human primary and xenograft gliomas. J Neuropath Exp Neurol 1998;57:1112–21.
11. Rempel SA, Golembieski WA, Ge S, Nelson K, Mikkelson T, Rempel SA. Increased SPARC expression promotes U87 glioblastoma invasion in vivo. J Dev Neurosci 1999;17:463–72.
12. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 2007;26:4084–94.
13. Schultz C, Lemeke N, Ge S, Golembieski WA, Rempel SA. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 2002;62:6270–77.
14. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003;278:15951–7.
15. Berens ME, Giese A. “...those left behind.” Biology and oncology of tumor stroma. Neoplasia 2003;5:188–199.
16. Funk SE, Sage EH. Differential effects of SPARC and catonic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 1993;154:53–63.
17. Funk SE, Sage EH. The Ca2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:2648–52.
18. Lopes MD. Angiogenesis in brain tumors. Microsc Res Tech 2003;63:69–70.
19. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on glioma endothelial cells. J Biol Chem 1998;273:2935–40.
20. Herold-Mende C, Andt T, Steiner HH, Riede D, Butterl A, Reisser C, Fusenig NE, Mueller MM. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999;79:1573–82.
21. Steiner H-H, Karcher S, Mueller MM, Nahbanits E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004;66:129–38.
22. Kaufman LJ, Brangwynne CP, Kasza KE, Filippidi E, Gordon VD, Deisboeck TS, Weitz DA. Glial expansion in collagen I matrices: analyzing collagen concentration-dependent growth and motility patterns. Biophys J 2005;89:635–50.
23. Davis GE, Senger DR. Endothelial extracellular matrix. Biosynthesis, remodeling, and functions during vascular morphogenesis and neurovessel stabilization. Circ Res 2005;97:1093–107.
24. Yan Q, Sage EH, SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999;47:1495–1505.
25. Honma K, Miyata T, Ochiya T. Type I collagen gene suppresses tumor growth and invasion of malignant human glioma cells. Cancer Cell Int 2007;7:12–21.
26. Chensiki A, Liu S, Guerero LJ, Yang Q, Tian Y, Salwen HR, Zape P, Cohen SL. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 2006;118:310–16.
27. Bangle R, Alford WC. The chemical basis of the periodic acid Schiff reaction of collagen fibers with reference to periodate consumption by collagen and by insulin. J Histochem Cytochem 1954;2:62–76.
28. Reed MJ, Bradshaw AD, Shaw M, Saddou E, Han N, Ferara N, Funk S, Pouakkainen P, Sage EH. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age. J Cell Physiol 2005;204:800–7.
29. Brewer CA, Settler DJ, Li MI, Johnston JM, Mann JL, McAsey ME. SPARC expression as a measure of microvesSEL density in cerebral cancer. Obstet Gynecol 2000;96:224–8.
30. Menon PM, Gutierrez JA, Rempel SA. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC expression correlates with decreased migration on vitronectin. Int J Oncol 2000;17:683–93.
31. Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 2001;53:149–60.
32. Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J. Loss of SPARC-mediated VEGFR1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 2006;116:422–9.
33. Golembieski WA, Rempel SA. cDNA array analysis of SPARC-modulated changes in glioma gene expression. J Neurooncol 2002;60:213–26.
34. Watarai M, Miwa H, Shikami M, Sugamura K, Wakahayashi M, Sato A, Tsuibo K, Imamura A, Mihara H, Katoh Y, Kita K, Nitta M. Expression of endothelial cell-associated molecules in AML cells. Leukemia 2002;16:112–19.
35. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugino M, Waene E, Perrin R, Foster R, Digby-Bell J, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action. In vivo effect on angiogenesis and endothigenic protein expression. Cancer Res 2004;64:7822–35.
36. Wilgos TA, Matthews AM, Radek KA, Dovi JV, Bums AL, Shankar R, DiPietro LA. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 2005;167:1257–66.
37. Reisenweber T, Ziv-Av A, Xiang C, Wu W, Caracau S, Taler D, Miller CG, Reich R, Shoshany A, Anikster Y, Kazimirkzgy G, Sarid R, et al. Related to testes-specific vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res 2006;66:4159–48.
Kowalczyk J, Domal-Kwiatkowska D, Mazurek U, Zembala M, Michalski B, Zembala M. Post translational modifications of VEGF-A mRNA in non-ischemic dilated cardiomyopathy. Cell Mol Lett 2007;12:331–47.

Livak KJ, Schmittgen TJ. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods 2001;25:402–8.

Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 2007;282:22062–71.

Yang S-Z, Zhang L-M, Huang Y-L, Sun F-Y. Distribution of FLK-1 and FLT-1 receptors in neonatal and adult rat brains. Anat Rec Part A 2003;274:851–56.

De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH, Byzova TV. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003;278:39044–50.

Bradshaw AD, Reed MJ, Carbon JG, Pinney E, Brekken RA, Sage EH. Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair Regen 2001;9:522–30.

Yan M, Schneider J, Gear R, Lu F, LaDow K, Warshawsky D, Helffinger SC. Expression of angiogenic factors is upregulated in DMBA-induced rat mammary pathologies. Pathobiology 2004;71:253–60.

Kraemer M, Tournaire R, Dejong V, Montreau N, Briege D, Derbin C, Binetruy B. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ 1999;10:193–200.

Cody NAL, Ouellet V, Manderson EN, Quinn MCJ, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson A-M, Chevre ette M, Tonin PN. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007;26:618–32.

Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahes paran R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, Chekenya M, Peters H, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006;103:16466–71.